STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLXNW
  4. [Form 4] Silexion Therapeutics Corp Insider Trading Activity

Silexion Therapeutics (SLXN) CSO logs sale-to-cover share transaction

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Silexion Therapeutics Corp CSO and CDO Shirvan Mitchell reported an open-market sale of 22,818 Ordinary Shares on March 26, 2026 at $1.36 per share. According to the footnotes, this was a sale-to-cover transaction to pay tax liabilities from a fully vested restricted share unit grant received on February 20, 2026.

After the sale, Mitchell directly held 27,889 Ordinary Shares. He also held a stock option over 478 Ordinary Shares with an exercise price of $907.71 per share and an expiration date of June 7, 2032, adjusted to reflect prior reverse share splits.

Positive

  • None.

Negative

  • None.
Insider Shirvan Mitchell
Role CSO and CDO
Sold 22,818 shs ($31K)
Type Security Shares Price Value
Sale Ordinary Shares 22,818 $1.36 $31K
holding Stock Option (right to buy Ordinary Shares) -- -- --
Holdings After Transaction: Ordinary Shares — 27,889 shares (Direct); Stock Option (right to buy Ordinary Shares) — 478 shares (Direct)
Footnotes (1)
  1. The transaction was a sale-to-cover to cover tax liability stemming from the Reporting Person's receipt of a grant of fully vested restricted share units on February 20, 2026, as reported in the Form 4 filed by the Reporting Person on February 23, 2026. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
Shares sold 22,818 Ordinary Shares Open-market sale on March 26, 2026
Sale price per share $1.36 per share Price for Ordinary Shares sold on March 26, 2026
Shares held after sale 27,889 Ordinary Shares Direct holdings following March 26, 2026 transaction
Option exercise price $907.71 per share Exercise price for option on 478 Ordinary Shares, expiring June 7, 2032
Option underlying shares 478 Ordinary Shares Underlying shares for stock option held directly
Reverse splits referenced 1-for-9 and 1-for-15 Adjustments to options and underlying shares for prior reverse share splits
sale-to-cover financial
"The transaction was a sale-to-cover to cover tax liability stemming from the Reporting Person's receipt of a grant"
restricted share units financial
"tax liability stemming from the Reporting Person's receipt of a grant of fully vested restricted share units"
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
Stock Option (right to buy Ordinary Shares) financial
"Stock Option (right to buy Ordinary Shares)"
reverse share split financial
"adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split"
A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.
Ordinary Shares financial
"Ordinary Shares"
Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Shirvan Mitchell
(Last)(First)(Middle)
C/O SILEXION THERAPEUTICS CORP
12 ABBA HILLEL ROAD
(Street)
RAMAT GAN5250606
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
CSO and CDO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares03/26/2026S(1)22,818D$1.3627,889D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy Ordinary Shares)(2)$907.71(3)08/15/202406/07/2032Ordinary Shares478(3)478(3)D
Explanation of Responses:
1. The transaction was a sale-to-cover to cover tax liability stemming from the Reporting Person's receipt of a grant of fully vested restricted share units on February 20, 2026, as reported in the Form 4 filed by the Reporting Person on February 23, 2026.
2. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
3. The number of options to purchase ordinary shares, underlying ordinary shares, and the exercise price of those options reported in this row have been adjusted to reflect a 1-for-9 reverse share split effected by the Issuer on November 29, 2024 and a 1-for-15 reverse share split effected by the Issuer on July 29, 2025.
/s/ Mirit Horenshtein Hadar, Attorney-in-fact03/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Silexion Therapeutics (SLXN) report for Shirvan Mitchell?

Silexion Therapeutics reported that CSO and CDO Shirvan Mitchell sold 22,818 Ordinary Shares on March 26, 2026 at $1.36 per share. The filing states this was a sale-to-cover transaction related to tax liabilities from a recent restricted share unit grant.

Why did Shirvan Mitchell sell Silexion Therapeutics (SLXN) shares in this Form 4?

The sale was described as a sale-to-cover to pay tax liabilities arising from Mitchell’s receipt of fully vested restricted share units on February 20, 2026. This indicates the disposition was tied to compensation and tax obligations rather than a purely discretionary sale.

How many Silexion Therapeutics (SLXN) shares does Shirvan Mitchell hold after the reported sale?

Following the March 26, 2026 transaction, Shirvan Mitchell directly held 27,889 Ordinary Shares. This post-transaction balance is disclosed in the Form 4 and represents his remaining direct equity position after completing the sale-to-cover trade.

What were the terms of the Silexion Therapeutics (SLXN) shares sold by Shirvan Mitchell?

Mitchell sold 22,818 Ordinary Shares at a reported price of $1.36 per share on March 26, 2026. The transaction is classified as an open-market sale, specifically identified as a sale-to-cover for associated tax liabilities on a restricted share unit grant.

What stock options does Shirvan Mitchell retain in Silexion Therapeutics (SLXN)?

Mitchell holds a stock option to purchase 478 Ordinary Shares with an exercise price of $907.71 per share, expiring June 7, 2032. The filing notes that the option terms and underlying shares were adjusted for 1-for-9 and 1-for-15 reverse share splits previously effected by the company.

Were there any trading plan or restructuring disclosures in the Silexion Therapeutics (SLXN) Form 4?

The Form 4 footnotes emphasize that the sale was to cover tax liabilities from a restricted share unit grant and that separate option holdings are reported for informational purposes. The excerpt does not reference a Rule 10b5-1 trading plan or ownership restructuring language.